501
|
Hsu C, Cheng A, Shih J, Yu C, Kuo S, Lin C, Huang T, Yang P, Yang C. Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma: A randomized phase II trial. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18072 Background: Epirubicin is active for treatment of non-small cell lung carcinoma (NSCLC) but its optimal dose was undetermined. This study was designed to evaluate the efficacy and safety of gemcitabine plus conventional-dose epirubicin for stage IIIB/IV NSCLC. Methods: Patients with histological or cytological diagnosis of stage IIIB/IV NSCLC who had not received prior chemotherapy were eligible. Patients were randomized to GE (gemcitabine, 1,000 mg/m2 on days 1, 8, and 15 and epirubicin, 70 mg/m2 on day 15) or GC (gemcitabine, 1,000 mg/m2 on days 1, 8, and 15 and cisplatin, 80 mg/m2 on day 15). Treatment cycles were repeated every 4 weeks. Objective tumor response and toxicity were evaluated by using the World Health Organization criteria. Results: No significant difference in baseline characteristics between patients randomized to GC (n=41) and GE (n=39) arms were found. The objective response rate was 31.0% (95% C.I. 16.4% to 45.5) for GC and 37.2.0% (95% C.I. 22.2% to 52.3%) for GE. The median time-to-treatment-failure and overall survival were 6.1 months (95% C.I. 4.9 to 7.4 months) and 13.2 months (95% C.I. 8.9 to 17.5 months) for GC and 6.2 months (95% C.I. 5.2 to 7.2 months) and 21.2 months (95% C.I. 14.6 to 27.8 months) for GE, respectively. More grade 3/4 neutropenia (71.8%) was noted in GE than in GC (43.9%). Febrile neutropenia was also more common in GE (4 patients) than in GC (1 patient). However, delay of protocol treatment due to leukopenia was similar between the 2 arms. Data on the expresssion of the excission repair cross-complimentation 1 (ERCC1), evaluated by immunohistochemical study for patients with available tumor tissue, will be presented. Conclusions: Gemcitabine plus conventional-dose epirubicin is an effective and well-tolerated regimen for patients with stage IIIB/IV NSCLC. No significant financial relationships to disclose.
Collapse
|
502
|
Huang C, Yang C, Yeh K, Hu F, Lin Z, Wan J, Tseng L, Yu C, Cheng A. The association of epidermal growth factor receptor ( EGFR) polymorphisms and clinicopathological factors with skin rash on gefitinib use. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18118 Background: Skin rash is the most common toxicity of EGFR-targeted therapy. Skin rash of EGFR inhibitor is associated with longer survival or tumor response. However, the clinical and genetic factors associated with this skin rash are not well understood. Methods: Fifty-two non-small-cell lung cancer patients enrolled in a prospective clinical trial of first-line gefitinib treatment were genotyped for EGFR intron 1 CA repeat polymorphism (CAn) and single nucleotide polymorphisms at promoters G-216T, C-191A, and R521K. Grade 2 to 3 skin rash within 4 weeks of treatment (early G2/3 rash) was correlated with the genotype and clinicopathological features of the patients by multivariate logistic regression. Results: Seventeen patients (32.7%) developed early G2/3 rash. In multivariate logistic regression analysis, only the CAn genotype was associated with early G2/3 rash and the effect was modified by patient age. Early G2/3 rash developed in 21% of patients with homozygous long allele (19 to 22 repeats, L) genotype (4/19), 31% of heterozygous short allele (15 to 18 repeats, S) / L genotype (8/26), and 71% of S/S genotype (5/7), respectively. The median ages of patients with early G2/3 rash and patients without early G2/3 rash were 57 years (range: 39–77) and 69 years (range: 43–86), respectively. The estimated logarithm of odds ratio (ln OR) for early G2/3 rash, as compared to S/S genotype, for S/L genotype was -0.038 multiplied by patient age (P = 0.011); and the ln OR for L/L genotype was -0.050 multiplied by patient age (P = 0.004). Fifty patients were evaluable for response. In logistic regression analysis, early G2/3 rash correlated with tumor response (P = 0.027). However, the CAn genotype was not significantly correlated with tumor response (P = 0.43). Conclusions: Homozygous short allele of EGFR CAn is more likely to develop skin rashes on gefitinib treatment. Genotyping of EGFR CAn appears to be a useful predictive marker for development of skin rashes on gefitinib use. [Table: see text]
Collapse
|
503
|
Friday B, Yu C, Yang L, Wigle D, Sarkaria J. Potentiation of proteasome inhibitor-induced apoptosis in glioma cells by histone deacetylase inhibitors. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.2038] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2038 The effects of combining histone deacetylase (HDAC) inhibitors and proteasome inhibitors were evaluated in both established glioblastoma multiforme (GBM) cell lines and short-term cultures derived from the Mayo Clinic xenograft GBM panel. Co-exposure of LBH589 (LBH) and botezomib (btzmb) results in a striking induction of apoptosis, at minimally toxic doses of either drug alone, in established U251, U87, and D37 GBM cell lines, as well as in GBM8 (G-8), GBM10 (G-10), GBM12 (G-12), GBM14 (G-14), and GBM56 (G-56) cells, which have been developed from the Mayo xenograft GBM panel and maintained in short-term cultures. Synergism of apoptosis induction was also observed in U251 cells when co-exposing other HDAC inhibitors, including LAQ824 (LAQ) and trichostatin A (TSA), with another proteasome inhibitor MG132, demonstarting a class effect. In U251 cells, btzmb alone or in combination with LBH decreased Raf-1 levels and inactivated Akt and Erk. Either LBH589 or bortezomib alone increased expression of the cell cycle regulators p21 and p27. Additionally, the combination, but not the individual agents, markedly increased JNK activation. In addition, cell death after exposure to LBH589 and bortezomib is associated with cytochrome c release, Bax translocation, as well as caspase and PARP cleavage. Bax translocation may contribute to the synergistic cytotoxicity of the combination of LBH and btzmb in glioma cells since Bax translocation to mitochondria is known to precede cytochrome c release and apoptosis, but other pathways are likely to be involved. This combination regimen warrants further preclinical and possible clinical study for glioma patients. No significant financial relationships to disclose.
Collapse
|
504
|
Kim T, Lee J, Lee J, Lee K, Kang Y, Yu C, Kim J, Ahn S, Kim J, Lee J. Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: A final report. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.4050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4050 Background: We conducted a prospective randomized trial to define the optimal sequence of chemotherapy and radiotherapy of postoperative adjuvant treatment in stage II and III rectal cancer. Methods: Three hundred eight patients were enrolled onto the study. We randomly assigned 155 to arm I (early radiotherapy group) and 153 to arm II (late radiotherapy group). Treatment included eight cycles of chemotherapy at 4-week intervals and pelvic radiotherapy of 45 Gy in 25 fractions. Radiotherapy started on day 1 of the first chemotherapy cycle in arm I and on day 1 of the third chemotherapy cycle in arm II. The chemotherapy regimen consisted of fluorouracil 375 mg/m2/d and leucovorin 20 mg/m2/d. Chemotherapy was administered for 3 days per cycle in two cycles during the period of radiotherapy and for 5 days per cycle in the remaining six cycles. (J Clin Oncol 2002 20:1751- 8) Results: Twenty patients in arm I and 14 in arm II were not eligible. We included 274 patients in the analysis. With a median follow-up of 94 months for surviving patients, there was a trend for improved disease-free survival(DFS) in arm I compared with arm II, although it was not reached statistical significance (72% v. 63% at 7 years; P =.157). Especially, in patients who received abdominoperineal resection (APR), DFS was prolonged in arm I compared with arm II (66% v. 41% at 7 years; P=.033) Thirty six recurrences (26.7%) occurred in arm I and 49 (35.3%) in arm II (P =.151). Overall survival was not significantly different between arms I and II (71% v. 68% at 7 years; P =.855). Conclusions: With a long-term follow-up, this study failed to show a significant survival advantage for early radiotherapy with concurrent chemotherapy after resection of stage II and III rectal cancer. In patients with APR, significant improvement in DFS for arm I was observed. No significant financial relationships to disclose.
Collapse
|
505
|
Chapman J, Meng D, Shepherd L, Parulekar W, Ingle JN, Muss HB, Palmer M, Yu C, Goss PE. Competing causes of death in NCIC CTG MA.17, a placebo-controlled trial of letrozole as extended adjuvant therapy for breast cancer patients. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.540] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
540 Background: Risk of death from other malignancies (OM) and other causes (OC) than breast cancer (BC) increases with age. Effects of baseline factors on type of death were assessed with competing risks analyses. Methods: In NCIC CTG MA.17, 5,187 women free of recurrent breast cancer after 5 years of tamoxifen were randomized to letrozole (L, 2,593 women) or placebo (P, 2,594 women). The primary endpoint was disease free survival (DFS), and secondary, overall survival (OS). Follow-up was to October 9, 2005: median 3.9 years, range <0.1 to 7.0 years. Effects of competing risks were examined for endpoints of BC, OM, and OC for 11 baseline trial factors: treatment, age, menopausal status, duration of prior tamoxifen, adjuvant radiotherapy, bone fracture, osteoporosis, cardiovascular disease, hormone receptor status, nodal status, adjuvant chemotherapy. Lagakos’ hierarchical method (Lagakos, Appl. Statist. 1978; 27:235–241) was used to test for differential effects of baseline factors on type of death (BC, OM, OC). Results: Rate of censoring was 97.8%, with 256 deaths (BC, 102; OM, 50; OC, 100; unknown, 4). Non-breast cancer deaths accounted for 60% of known deaths; 72%, for those ≥70 years; and 48%, for those <70 years. Two baseline factors differentially affected type of death. Women with cardiovascular disease were more likely to die from OC (p=0.02), while those with osteoporosis were more likely to die of OM (p=0.03). Age and nodal status had directionally similar effects. Older women had shorter survival from all 3 causes of death (p=0.01). Lymph node positivity was associated with worse survival (p=0.003). Conclusions: Extended L provides similar proportional benefit in improving DFS for all ages of women (Muss ref abstract SABCS 2006). However, the magnitude of competing non-breast cancer, and non-treatment related, causes of death needs to be considered more frequently, since with early detection and improved therapies, breast cancer patients may increasingly be expected to survive their disease to die from another cause. The novel association between baseline osteoporosis and other malignancies is being explored quantitatively. No significant financial relationships to disclose.
Collapse
|
506
|
Han-Oh Y, Yi B, Lerma F, Berman B, Yu C. SU-FF-J-132: A Novel Technique for Closed-Loop Feedback Real-Time Tracking by Controlling Dose Rate : A Parametric Study. Med Phys 2007. [DOI: 10.1118/1.2760637] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
507
|
Ha J, Perlow D, Yu C. TU-C-M100J-07: A Systematic Study On the Sources of Drift in a Turbine-Based Spirometer Using a Breathing Simulator. Med Phys 2007. [DOI: 10.1118/1.2761338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
508
|
Luan S, Wang C, Cao D, Chen D, Shepard D, Yu C. TH-C-AUD-01: IMAT Leaf Sequencing Using Graph Algorithms. Med Phys 2007. [DOI: 10.1118/1.2761660] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
509
|
Navoa-Ng J, Rosenthal V, Asetre-Luna I, Yu C. Healthcare-Associated Infection Rates, Extra Length of Stay and Mortality in a Hospital of the Philippines. Findings of the INICC. Am J Infect Control 2007. [DOI: 10.1016/j.ajic.2007.04.055] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
510
|
Djajaputra D, Lo A, Gibbs I, Yu C. SU-FF-T-112: Commissioning of a CyberKnife G4 System at Stanford University Medical Center. Med Phys 2007. [DOI: 10.1118/1.2760768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
511
|
Zhang G, Yi B, Jiang Z, Yu C. MO-D-M100J-06: Reducing Intra-Fraction Organ Motion Effects Using Segment Size Constraint in Direct Aperture Optimization. Med Phys 2007. [DOI: 10.1118/1.2761248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
512
|
Tang G, Earl M, Yu C, Naqvi S. TU-D-AUD-08: Monte Carlo Kernel-Based Convolution-Superposition Dose Calculation for Intensity-Modulated Arc Therapy (IMAT). Med Phys 2007. [DOI: 10.1118/1.2761387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
513
|
Yu C, Pagnini P, Giannotta S, Apuzzo M. SU-FF-T-395: System Accuracy Of Leksell Gamma Knife Stereotactic Radiosurgery. Med Phys 2007. [DOI: 10.1118/1.2761120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
514
|
Yi B, Lerma F, Han-Oh Y, Yu C. SU-FF-T-191: Dual Window Gated Beam Delivery for Stereotactic Body Radiotherapy. Med Phys 2007. [DOI: 10.1118/1.2760851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
515
|
Lo A, Djajaputra D, Yu C. SU-FF-T-265: Initial Experience with a CyberKnife G4 System. Med Phys 2007. [DOI: 10.1118/1.2760926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
516
|
Abazov VM, Abbott B, Abolins M, Acharya BS, Adams M, Adams T, Aguilo E, Ahn SH, Ahsan M, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Anastasoaie M, Ancu LS, Andeen T, Anderson S, Andrieu B, Anzelc MS, Arnoud Y, Arov M, Askew A, Asman B, Assis Jesus ACS, Atramentov O, Autermann C, Avila C, Ay C, Badaud F, Baden A, Bagby L, Baldin B, Bandurin DV, Banerjee P, Banerjee S, Barberis E, Bargassa P, Baringer P, Barnes C, Barreto J, Bartlett JF, Bassler U, Bauer D, Beale S, Bean A, Begalli M, Begel M, Belanger-Champagne C, Bellantoni L, Bellavance A, Benitez JA, Beri SB, Bernardi G, Bernhard R, Berntzon L, Bertram I, Besançon M, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Binder M, Biscarat C, Blackler I, Blazey G, Blekman F, Blessing S, Bloch D, Bloom K, Boehnlein A, Boline D, Bolton TA, Borissov G, Bos K, Bose T, Brandt A, Brock R, Brooijmans G, Bross A, Brown D, Buchanan NJ, Buchholz D, Buehler M, Buescher V, Burdin S, Burke S, Burnett TH, Busato E, Buszello CP, Butler JM, Calfayan P, Calvet S, Cammin J, Caron S, Carvalho W, Casey BCK, Cason NM, Castilla-Valdez H, Chakrabarti S, Chakraborty D, Chan KM, Chandra A, Charles F, Cheu E, Chevallier F, Cho DK, Choi S, Choudhary B, Christofek L, Claes D, Clément B, Clément C, Coadou Y, Cooke M, Cooper WE, Corcoran M, Couderc F, Cousinou MC, Cox B, Crépé-Renaudin S, Cutts D, Cwiok M, da Motta H, Das A, Das M, Davies B, Davies G, De K, de Jong P, de Jong SJ, De La Cruz-Burelo E, De Oliveira Martins C, Degenhardt JD, Déliot F, Demarteau M, Demina R, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Doidge M, Dominguez A, Dong H, Dudko LV, Duflot L, Dugad SR, Duggan D, Duperrin A, Dyer J, Dyshkant A, Eads M, Edmunds D, Ellison J, Elvira VD, Enari Y, Eno S, Ermolov P, Evans H, Evdokimov A, Evdokimov VN, Feligioni L, Ferapontov AV, Ferbel T, Fiedler F, Filthaut F, Fisher W, Fisk HE, Ford M, Fortner M, Fox H, Fu S, Fuess S, Gadfort T, Galea CF, Gallas E, Galyaev E, Garcia C, Garcia-Bellido A, Gavrilov V, Gay A, Gay P, Geist W, Gelé D, Gelhaus R, Gerber CE, Gershtein Y, Gillberg D, Ginther G, Gollub N, Gómez B, Goussiou A, Grannis PD, Greenlee H, Greenwood ZD, Gregores EM, Grenier G, Gris P, Grivaz JF, Grohsjean A, Grünendahl S, Grünewald MW, Guo F, Guo J, Gutierrez G, Gutierrez P, Haas A, Hadley NJ, Haefner P, Hagopian S, Haley J, Hall I, Hall RE, Han L, Hanagaki K, Hansson P, Harder K, Harel A, Harrington R, Hauptman JM, Hauser R, Hays J, Hebbeker T, Hedin D, Hegeman JG, Heinmiller JM, Heinson AP, Heintz U, Hensel C, Herner K, Hesketh G, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Hoeth H, Hohlfeld M, Hong SJ, Hooper R, Houben P, Hu Y, Hubacek Z, Hynek V, Iashvili I, Illingworth R, Ito AS, Jabeen S, Jaffré M, Jain S, Jakobs K, Jarvis C, Jenkins A, Jesik R, Johns K, Johnson C, Johnson M, Jonckheere A, Jonsson P, Juste A, Käfer D, Kahn S, Kajfasz E, Kalinin AM, Kalk JM, Kalk JR, Kappler S, Karmanov D, Kasper J, Kasper P, Katsanos I, Kau D, Kaur R, Kehoe R, Kermiche S, Khalatyan N, Khanov A, Kharchilava A, Kharzheev YM, Khatidze D, Kim H, Kim TJ, Kirby MH, Klima B, Kohli JM, Konrath JP, Kopal M, Korablev VM, Kotcher J, Kothari B, Koubarovsky A, Kozelov AV, Krop D, Kryemadhi A, Kuhl T, Kumar A, Kunori S, Kupco A, Kurca T, Kvita J, Lam D, Lammers S, Landsberg G, Lazoflores J, Le Bihan AC, Lebrun P, Lee WM, Leflat A, Lehner F, Lesne V, Leveque J, Lewis P, Li J, Li L, Li QZ, Lietti SM, Lima JGR, Lincoln D, Linnemann J, Lipaev VV, Lipton R, Liu Z, Lobo L, Lobodenko A, Lokajicek M, Lounis A, Love P, Lubatti HJ, Lynker M, Lyon AL, Maciel AKA, Madaras RJ, Mättig P, Magass C, Magerkurth A, Makovec N, Mal PK, Malbouisson HB, Malik S, Malyshev VL, Mao HS, Maravin Y, McCarthy R, Melnitchouk A, Mendes A, Mendoza L, Mercadante PG, Merkin M, Merritt KW, Meyer A, Meyer J, Michaut M, Miettinen H, Millet T, Mitrevski J, Molina J, Mommsen RK, Mondal NK, Monk J, Moore RW, Moulik T, Muanza GS, Mulders M, Mulhearn M, Mundal O, Mundim L, Nagy E, Naimuddin M, Narain M, Naumann NA, Neal HA, Negret JP, Neustroev P, Noeding C, Nomerotski A, Novaes SF, Nunnemann T, O'Dell V, O'Neil DC, Obrant G, Ochando C, Oguri V, Oliveira N, Onoprienko D, Oshima N, Osta J, Otec R, Otero Y Garzón GJ, Owen M, Padley P, Pangilinan M, Parashar N, Park SJ, Park SK, Parsons J, Partridge R, Parua N, Patwa A, Pawloski G, Perea PM, Peters K, Peters Y, Pétroff P, Petteni M, Piegaia R, Piper J, Pleier MA, Podesta-Lerma PLM, Podstavkov VM, Pogorelov Y, Pol ME, Pompos A, Pope BG, Popov AV, Potter C, Prado da Silva WL, Prosper HB, Protopopescu S, Qian J, Quadt A, Quinn B, Rangel MS, Rani KJ, Ranjan K, Ratoff PN, Renkel P, Reucroft S, Rijssenbeek M, Ripp-Baudot I, Rizatdinova F, Robinson S, Rodrigues RF, Royon C, Rubinov P, Ruchti R, Sajot G, Sánchez-Hernández A, Sanders MP, Santoro A, Savage G, Sawyer L, Scanlon T, Schaile D, Schamberger RD, Scheglov Y, Schellman H, Schieferdecker P, Schmitt C, Schwanenberger C, Schwartzman A, Schwienhorst R, Sekaric J, Sengupta S, Severini H, Shabalina E, Shamim M, Shary V, Shchukin AA, Shivpuri RK, Shpakov D, Siccardi V, Sidwell RA, Simak V, Sirotenko V, Skubic P, Slattery P, Smith RP, Snow GR, Snow J, Snyder S, Söldner-Rembold S, Song X, Sonnenschein L, Sopczak A, Sosebee M, Soustruznik K, Souza M, Spurlock B, Stark J, Steele J, Stolin V, Stone A, Stoyanova DA, Strandberg J, Strandberg S, Strang MA, Strauss M, Ströhmer R, Strom D, Strovink M, Stutte L, Sumowidagdo S, Svoisky P, Sznajder A, Talby M, Tamburello P, Taylor W, Telford P, Temple J, Tiller B, Titov M, Tokmenin VV, Tomoto M, Toole T, Torchiani I, Trefzger T, Trincaz-Duvoid S, Tsybychev D, Tuchming B, Tully C, Tuts PM, Unalan R, Uvarov L, Uvarov S, Uzunyan S, Vachon B, van den Berg PJ, van Eijk B, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vartapetian A, Vasilyev IA, Vaupel M, Verdier P, Vertogradov LS, Verzocchi M, Villeneuve-Seguier F, Vint P, Vlimant JR, Von Toerne E, Voutilainen M, Vreeswijk M, Wahl HD, Wang L, Wang MHLS, Warchol J, Watts G, Wayne M, Weber G, Weber M, Weerts H, Wermes N, Wetstein M, White A, Wicke D, Wilson GW, Wimpenny SJ, Wobisch M, Womersley J, Wood DR, Wyatt TR, Xie Y, Yacoob S, Yamada R, Yan M, Yasuda T, Yatsunenko YA, Yip K, Yoo HD, Youn SW, Yu C, Yu J, Yurkewicz A, Zatserklyaniy A, Zeitnitz C, Zhang D, Zhao T, Zhou B, Zhu J, Zielinski M, Zieminska D, Zieminski A, Zutshi V, Zverev EG. Search for techniparticles in e+jets events at D0. PHYSICAL REVIEW LETTERS 2007; 98:221801. [PMID: 17677833 DOI: 10.1103/physrevlett.98.221801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/08/2006] [Indexed: 05/16/2023]
Abstract
We search for the technicolor process pp-->rhoT/omegaT-->WpiT in events containing one electron and two jets, in data corresponding to an integrated luminosity of 390 pb(-1), recorded by the D0 experiment at the Fermilab Tevatron. Technicolor predicts that technipions pi(T) decay dominantly into bb, bc, or bc, depending on their charge. In these events b and c quarks are identified by their secondary decay vertices within jets. Two analysis methods based on topological variables are presented. Since no excess above the standard model prediction was found, the result is presented as an exclusion in the pi(T) vs rho(T) mass plane for a given set of model parameters.
Collapse
|
517
|
Pretorius MM, Gainer JV, Van Guilder GP, Coelho EB, Luther JM, Fong P, Rosenbaum DD, Malave HA, Yu C, Ritchie MD, Vaughan DE, Brown NJ. The Bradykinin Type 2 Receptor BE1 Polymorphism and Ethnicity Influence Systolic Blood Pressure and Vascular Resistance. Clin Pharmacol Ther 2007; 83:122-9. [PMID: 17522594 DOI: 10.1038/sj.clpt.6100250] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We examined the effect of -58 C/T and BE1 +9/-9 polymorphisms in the bradykinin B2 receptor gene on forearm vascular resistance (FVR) before and during intrabrachial artery infusion of the B2 receptor-, endothelium-dependent agonist bradykinin and the endothelium-independent agonist sodium nitroprusside in 228 normotensive subjects. In 166 white Americans, systolic blood pressure (SBP) and pulse pressure were highest in the BE1 +9/+9 group (118+/-2 and 51+/-2 mm Hg, respectively; P<0.05 versus -9/-9 for either), intermediate in the +9/-9 group (114+/-1 and 49+/-1 mm Hg, P<0.05 versus -9/-9 for pulse pressure), and lowest in the -9/-9 group (110+/-2 and 44+/-2 mm Hg). In 62 black Americans, FVR was 25% higher in the BE1 +9/+9 group compared with the BE1 +9/-9 and -9/-9 groups at baseline (P=0.038) or during bradykinin (P=0.03). Increased SBP or vascular resistance may contribute to increased left ventricular mass reported previously in individuals with the BE1+9/+9 genotype.
Collapse
|
518
|
Avalos I, Chung CP, Oeser A, Milne GL, Morrow JD, Gebretsadik T, Shintani A, Yu C, Stein CM. Oxidative stress in systemic lupus erythematosus: relationship to disease activity and symptoms. Lupus 2007; 16:195-200. [PMID: 17432105 DOI: 10.1177/0961203306075802] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Oxidative stress may play a role in the pathogenesis of systemic lupus erythematosus (SLE). We examined the hypothesis that oxidative stress was associated with indices of lupus disease activity and severity of symptoms. Urinary F2 isoprostane excretion, a validated marker of oxidative stress, was measured in 95 patients with SLE and 103 healthy controls. Outcome measures included SLEDAI and SLICC scores, the modified health assessment questionnaire, the fatigue severity scale (FSS), and visual analogue scales (VAS) for fatigue, pain and overall disease activity. F2 isoprostane excretion was compared in patients and controls, and its relationship with clinical variables in SLE examined. F2 isoprostane excretion did not differ significantly among patients with lupus (2.7 +/- 2.3 ng/mg Cr) and control subjects (2.2 +/- 1.4 ng/mg Cr) (P = 0.70). In patients with lupus, F2 isoprostane concentrations were independently associated with higher patient reported disease activity (VAS) (OR = 1.52, P = 0.01), fatigue (FSS, OR = 1.52, P = 0.03) and lower quality of life (OR = 0.73, P = 0.05), but not with objective markers or inflammation or disease activity. In conclusion, F2 isoprostane excretion is associated with patient-reported symptoms in SLE but not with measures of inflammation, SLEDAI or SLICC. Oxidative stress may contribute to debilitating symptoms such as fatigue in SLE.
Collapse
|
519
|
Abazov VM, Abbott B, Abolins M, Acharya BS, Adams M, Adams T, Aguilo E, Ahn SH, Ahsan M, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Anastasoaie M, Ancu LS, Andeen T, Anderson S, Andrieu B, Anzelc MS, Arnoud Y, Arov M, Askew A, Asman B, Assis Jesus ACS, Atramentov O, Autermann C, Avila C, Ay C, Badaud F, Baden A, Bagby L, Baldin B, Bandurin DV, Banerjee P, Banerjee S, Barberis E, Bargassa P, Baringer P, Barnes C, Barreto J, Bartlett JF, Bassler U, Bauer D, Beale S, Bean A, Begalli M, Begel M, Belanger-Champagne C, Bellantoni L, Bellavance A, Benitez JA, Beri SB, Bernardi G, Bernhard R, Berntzon L, Bertram I, Besançon M, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Binder M, Biscarat C, Blackler I, Blazey G, Blekman F, Blessing S, Bloch D, Bloom K, Boehnlein A, Boline D, Bolton TA, Boos EE, Borissov G, Bos K, Bose T, Brandt A, Brock R, Brooijmans G, Bross A, Brown D, Buchanan NJ, Buchholz D, Buehler M, Buescher V, Bunichev V, Burdin S, Burke S, Burnett TH, Busato E, Buszello CP, Butler JM, Calfayan P, Calvet S, Cammin J, Caron S, Carvalho W, Casey BCK, Cason NM, Castilla-Valdez H, Chakrabarti S, Chakraborty D, Chan KM, Chandra A, Charles F, Cheu E, Chevallier F, Cho DK, Choi S, Choudhary B, Christofek L, Claes D, Clément B, Clément C, Coadou Y, Cooke M, Cooper WE, Corcoran M, Couderc F, Cousinou MC, Cox B, Crépé-Renaudin S, Cutts D, Cwiok M, da Motta H, Das A, Das M, Davies B, Davies G, De K, de Jong P, de Jong SJ, De La Cruz-Burelo E, De Oliveira Martins C, Degenhardt JD, Déliot F, Demarteau M, Demina R, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Doidge M, Dominguez A, Dong H, Dudko LV, Duflot L, Dugad SR, Duggan D, Duperrin A, Dyer J, Dyshkant A, Eads M, Edmunds D, Ellison J, Elvira VD, Enari Y, Eno S, Ermolov P, Evans H, Evdokimov A, Evdokimov VN, Feligioni L, Ferapontov AV, Ferbel T, Fiedler F, Filthaut F, Fisher W, Fisk HE, Ford M, Fortner M, Fox H, Fu S, Fuess S, Gadfort T, Galea CF, Gallas E, Galyaev E, Garcia C, Garcia-Bellido A, Gavrilov V, Gay A, Gay P, Geist W, Gelé D, Gelhaus R, Gerber CE, Gershtein Y, Gillberg D, Ginther G, Gollub N, Gómez B, Goussiou A, Grannis PD, Greenlee H, Greenwood ZD, Gregores EM, Grenier G, Gris P, Grivaz JF, Grohsjean A, Grünendahl S, Grünewald MW, Guo F, Guo J, Gutierrez G, Gutierrez P, Haas A, Hadley NJ, Haefner P, Hagopian S, Haley J, Hall I, Hall RE, Han L, Hanagaki K, Hansson P, Harder K, Harel A, Harrington R, Hauptman JM, Hauser R, Hays J, Hebbeker T, Hedin D, Hegeman JG, Heinmiller JM, Heinson AP, Heintz U, Hensel C, Herner K, Hesketh G, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Hoeth H, Hohlfeld M, Hong SJ, Hooper R, Houben P, Hu Y, Hubacek Z, Hynek V, Iashvili I, Illingworth R, Ito AS, Jabeen S, Jaffré M, Jain S, Jakobs K, Jarvis C, Jenkins A, Jesik R, Johns K, Johnson C, Johnson M, Jonckheere A, Jonsson P, Juste A, Käfer D, Kahn S, Kajfasz E, Kalinin AM, Kalk JM, Kalk JR, Kappler S, Karmanov D, Kasper J, Kasper P, Katsanos I, Kau D, Kaur R, Kehoe R, Kermiche S, Khalatyan N, Khanov A, Kharchilava A, Kharzheev YM, Khatidze D, Kim H, Kim TJ, Kirby MH, Klima B, Kohli JM, Konrath JP, Kopal M, Korablev VM, Kotcher J, Kothari B, Koubarovsky A, Kozelov AV, Krop D, Kryemadhi A, Kuhl T, Kumar A, Kunori S, Kupco A, Kurca T, Kvita J, Lam D, Lammers S, Landsberg G, Lazoflores J, Le Bihan AC, Lebrun P, Lee WM, Leflat A, Lehner F, Lesne V, Leveque J, Lewis P, Li J, Li L, Li QZ, Lietti SM, Lima JGR, Lincoln D, Linnemann J, Lipaev VV, Lipton R, Liu Z, Lobo L, Lobodenko A, Lokajicek M, Lounis A, Love P, Lubatti HJ, Lynker M, Lyon AL, Maciel AKA, Madaras RJ, Mättig P, Magass C, Magerkurth A, Makovec N, Mal PK, Malbouisson HB, Malik S, Malyshev VL, Mao HS, Maravin Y, McCarthy R, Melnitchouk A, Mendes A, Mendoza L, Mercadante PG, Merkin M, Merritt KW, Meyer A, Meyer J, Michaut M, Miettinen H, Millet T, Mitrevski J, Molina J, Mommsen RK, Mondal NK, Monk J, Moore RW, Moulik T, Muanza GS, Mulders M, Mulhearn M, Mundal O, Mundim L, Nagy E, Naimuddin M, Narain M, Naumann NA, Neal HA, Negret JP, Neustroev P, Noeding C, Nomerotski A, Novaes SF, Nunnemann T, O'Dell V, O'Neil DC, Obrant G, Ochando C, Oguri V, Oliveira N, Onoprienko D, Oshima N, Osta J, Otec R, Otero Y Garzón GJ, Owen M, Padley P, Pangilinan M, Parashar N, Park SJ, Park SK, Parsons J, Partridge R, Parua N, Patwa A, Pawloski G, Perea PM, Perfilov M, Peters K, Peters Y, Pétroff P, Petteni M, Piegaia R, Piper J, Pleier MA, Podesta-Lerma PLM, Podstavkov VM, Pogorelov Y, Pol ME, Pompos A, Pope BG, Popov AV, Potter C, Prado da Silva WL, Prosper HB, Protopopescu S, Qian J, Quadt A, Quinn B, Rangel MS, Rani KJ, Ranjan K, Ratoff PN, Renkel P, Reucroft S, Rijssenbeek M, Ripp-Baudot I, Rizatdinova F, Robinson S, Rodrigues RF, Royon C, Rubinov P, Ruchti R, Sajot G, Sánchez-Hernández A, Sanders MP, Santoro A, Savage G, Sawyer L, Scanlon T, Schaile D, Schamberger RD, Scheglov Y, Schellman H, Schieferdecker P, Schmitt C, Schwanenberger C, Schwartzman A, Schwienhorst R, Sekaric J, Sengupta S, Severini H, Shabalina E, Shamim M, Shary V, Shchukin AA, Shivpuri RK, Shpakov D, Siccardi V, Sidwell RA, Simak V, Sirotenko V, Skubic P, Slattery P, Smith RP, Snow GR, Snow J, Snyder S, Söldner-Rembold S, Song X, Sonnenschein L, Sopczak A, Sosebee M, Soustruznik K, Souza M, Spurlock B, Stark J, Steele J, Stolin V, Stone A, Stoyanova DA, Strandberg J, Strandberg S, Strang MA, Strauss M, Ströhmer R, Strom D, Strovink M, Stutte L, Sumowidagdo S, Svoisky P, Sznajder A, Talby M, Tamburello P, Taylor W, Telford P, Temple J, Tiller B, Titov M, Tokmenin VV, Tomoto M, Toole T, Torchiani I, Trefzger T, Trincaz-Duvoid S, Tsybychev D, Tuchming B, Tully C, Tuts PM, Unalan R, Uvarov L, Uvarov S, Uzunyan S, Vachon B, van den Berg PJ, van Eijk B, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vartapetian A, Vasilyev IA, Vaupel M, Verdier P, Vertogradov LS, Verzocchi M, Vetterli M, Villeneuve-Seguier F, Vint P, Vlimant JR, Von Toerne E, Voutilainen M, Vreeswijk M, Wahl HD, Wang L, Wang MHLS, Warchol J, Watts G, Wayne M, Weber G, Weber M, Weerts H, Wermes N, Wetstein M, White A, Wicke D, Wilson GW, Wimpenny SJ, Wobisch M, Womersley J, Wood DR, Wyatt TR, Xie Y, Yacoob S, Yamada R, Yan M, Yasuda T, Yatsunenko YA, Yip K, Yoo HD, Youn SW, Yu C, Yu J, Yurkewicz A, Zatserklyaniy A, Zeitnitz C, Zhang D, Zhao T, Zhou B, Zhu J, Zielinski M, Zieminska D, Zieminski A, Zutshi V, Zverev EG. Evidence for production of single top quarks and first direct measurement of |Vtb|. PHYSICAL REVIEW LETTERS 2007; 98:181802. [PMID: 17501561 DOI: 10.1103/physrevlett.98.181802] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/22/2006] [Indexed: 05/15/2023]
Abstract
The D0 Collaboration presents first evidence for the production of single top quarks at the Fermilab Tevatron pp[over ] collider. Using a 0.9 fb(-1) dataset, we apply a multivariate analysis to separate signal from background and measure sigma(pp[over ]-->tb+X,tqb+X)=4.9+/-1.4 pb. The probability to measure a cross section at this value or higher in the absence of a signal is 0.035%, corresponding to a 3.4 standard deviation significance. We use the cross section measurement to directly determine the Cabibbo-Kobayashi-Maskawa matrix element that describes the Wtb coupling and find 0.68<|V(tb)|</=1 at 95% C.L. within the standard model.
Collapse
|
520
|
Chen S, Ding J, Yu C, Yang B, Wood DR, Grayburn PA. Reversal of streptozotocin-induced diabetes in rats by gene therapy with betacellulin and pancreatic duodenal homeobox-1. Gene Ther 2007; 14:1102-10. [PMID: 17460716 DOI: 10.1038/sj.gt.3302963] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Ultrasound-targeted microbubble destruction (UTMD) was used to direct betacellulin (BTC) and pancreatic duodenal homeobox-1 (PDX1) to rat pancreas 48 h after islet destruction by streptozotocin (STZ). Sprague-Dawley rats were rendered diabetic by STZ injection. Controls included normal rats, STZ only without UTMD, and UTMD with DsRed reporter gene. Blood glucose increased dramatically in all rats 48 h after STZ, and continued to rise after UTMD with BTC alone. Blood glucose declined from day 3 to day 10 after UTMD with PDX1, but remained elevated (261+/-8 mg/dl). However, in rats treated with both BTC and PDX1, blood glucose remained below 200 mg/dl throughout day 10. This was accompanied by normalization of blood insulin and C-peptide. Histology demonstrated islet-like clusters of glucagon-staining cells in the rats treated with BTC and PDX1, but these clusters disappeared by 30 days after UTMD treatment. Although regeneration of insulin-producing islets was not seen, diabetes was reversed for up to 15 days after a single UTMD treatment by ectopic insulin production by pancreatic acinar cells. These cells co-expressed amylase and insulin and demonstrated several beta-cell markers by reverse transcription-PCR. Gene therapy by UTMD can reverse diabetes in vivo in adult rats by restoring pancreatic insulin production.
Collapse
|
521
|
Abazov VM, Abbott B, Abolins M, Acharya BS, Adams M, Adams T, Aguilo E, Ahn SH, Ahsan M, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Anastasoaie M, Ancu LS, Andeen T, Anderson S, Andrieu B, Anzelc MS, Arnoud Y, Arov M, Askew A, Asman B, Assis Jesus ACS, Atramentov O, Autermann C, Avila C, Ay C, Badaud F, Baden A, Bagby L, Baldin B, Bandurin DV, Banerjee P, Banerjee S, Barberis E, Bargassa P, Baringer P, Barnes C, Barreto J, Bartlett JF, Bassler U, Bauer D, Beale S, Bean A, Begalli M, Begel M, Belanger-Champagne C, Bellantoni L, Bellavance A, Benitez JA, Beri SB, Bernardi G, Bernhard R, Berntzon L, Bertram I, Besançon M, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Binder M, Biscarat C, Blackler I, Blazey G, Blekman F, Blessing S, Bloch D, Bloom K, Boehnlein A, Boline D, Bolton TA, Borissov G, Bos K, Bose T, Brandt A, Brock R, Brooijmans G, Bross A, Brown D, Buchanan NJ, Buchholz D, Buehler M, Buescher V, Burdin S, Burke S, Burnett TH, Busato E, Buszello CP, Butler JM, Calfayan P, Calvet S, Cammin J, Caron S, Carvalho W, Casey BCK, Cason NM, Castilla-Valdez H, Chakrabarti S, Chakraborty D, Chan KM, Chandra A, Charles F, Cheu E, Chevallier F, Cho DK, Choi S, Choudhary B, Christofek L, Claes D, Clément B, Clément C, Coadou Y, Cooke M, Cooper WE, Corcoran M, Couderc F, Cousinou MC, Cox B, Crépé-Renaudin S, Cutts D, Cwiok M, da Motta H, Das A, Das M, Davies B, Davies G, De K, de Jong P, de Jong SJ, De La Cruz-Burelo E, De Oliveira Martins C, Degenhardt JD, Déliot F, Demarteau M, Demina R, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Doidge M, Dominguez A, Dong H, Dudko LV, Duflot L, Dugad SR, Duggan D, Duperrin A, Dyer J, Dyshkant A, Eads M, Edmunds D, Ellison J, Elvira VD, Enari Y, Eno S, Ermolov P, Evans H, Evdokimov A, Evdokimov VN, Feligioni L, Ferapontov AV, Ferbel T, Fiedler F, Filthaut F, Fisher W, Fisk HE, Ford M, Fortner M, Fox H, Fu S, Fuess S, Gadfort T, Galea CF, Gallas E, Galyaev E, Garcia C, Garcia-Bellido A, Gavrilov V, Gay A, Gay P, Geist W, Gelé D, Gelhaus R, Gerber CE, Gershtein Y, Gillberg D, Ginther G, Gollub N, Gómez B, Goussiou A, Grannis PD, Greenlee H, Greenwood ZD, Gregores EM, Grenier G, Gris P, Grivaz JF, Grohsjean A, Grünendahl S, Grünewald MW, Guo F, Guo J, Gutierrez G, Gutierrez P, Haas A, Hadley NJ, Haefner P, Hagopian S, Haley J, Hall I, Hall RE, Han L, Hanagaki K, Hansson P, Harder K, Harel A, Harrington R, Hauptman JM, Hauser R, Hays J, Hebbeker T, Hedin D, Hegeman JG, Heinmiller JM, Heinson AP, Heintz U, Hensel C, Herner K, Hesketh G, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Hoeth H, Hohlfeld M, Holubyev K, Hong SJ, Hooper R, Houben P, Hu Y, Hubacek Z, Hynek V, Iashvili I, Illingworth R, Ito AS, Jabeen S, Jaffré M, Jain S, Jakobs K, Jarvis C, Jenkins A, Jesik R, Johns K, Johnson C, Johnson M, Jonckheere A, Jonsson P, Juste A, Käfer D, Kahn S, Kajfasz E, Kalinin AM, Kalk JM, Kalk JR, Kappler S, Karmanov D, Kasper J, Kasper P, Katsanos I, Kau D, Kaur R, Kehoe R, Kermiche S, Khalatyan N, Khanov A, Kharchilava A, Kharzheev YM, Khatidze D, Kim H, Kim TJ, Kirby MH, Klima B, Kohli JM, Konrath JP, Kopal M, Korablev VM, Kotcher J, Kothari B, Koubarovsky A, Kozelov AV, Krop D, Kryemadhi A, Kuhl T, Kumar A, Kunori S, Kupco A, Kurca T, Kvita J, Lam D, Lammers S, Landsberg G, Lazoflores J, Le Bihan AC, Lebrun P, Lee WM, Leflat A, Lehner F, Lesne V, Leveque J, Lewis P, Li J, Li L, Li QZ, Lietti SM, Lima JGR, Lincoln D, Linnemann J, Lipaev VV, Lipton R, Liu Z, Lobo L, Lobodenko A, Lokajicek M, Lounis A, Love P, Lubatti HJ, Lynker M, Lyon AL, Maciel AKA, Madaras RJ, Mättig P, Magass C, Magerkurth A, Makovec N, Mal PK, Malbouisson HB, Malik S, Malyshev VL, Mao HS, Maravin Y, McCarthy R, Melnitchouk A, Mendes A, Mendoza L, Mercadante PG, Merkin M, Merritt KW, Meyer A, Meyer J, Michaut M, Miettinen H, Millet T, Mitrevski J, Molina J, Mommsen RK, Mondal NK, Monk J, Moore RW, Moulik T, Muanza GS, Mulders M, Mulhearn M, Mundal O, Mundim L, Nagy E, Naimuddin M, Narain M, Naumann NA, Neal HA, Negret JP, Neustroev P, Noeding C, Nomerotski A, Novaes SF, Nunnemann T, O'Dell V, O'Neil DC, Obrant G, Ochando C, Oguri V, Oliveira N, Onoprienko D, Oshima N, Osta J, Otec R, Otero Y Garzón GJ, Owen M, Padley P, Pangilinan M, Parashar N, Park SJ, Park SK, Parsons J, Partridge R, Parua N, Patwa A, Pawloski G, Perea PM, Peters K, Peters Y, Pétroff P, Petteni M, Piegaia R, Piper J, Pleier MA, Podesta-Lerma PLM, Podstavkov VM, Pogorelov Y, Pol ME, Pompos A, Pope BG, Popov AV, Potter C, Prado da Silva WL, Prosper HB, Protopopescu S, Qian J, Quadt A, Quinn B, Rangel MS, Rani KJ, Ranjan K, Ratoff PN, Renkel P, Reucroft S, Rijssenbeek M, Ripp-Baudot I, Rizatdinova F, Robinson S, Rodrigues RF, Royon C, Rubinov P, Ruchti R, Sajot G, Sánchez-Hernández A, Sanders MP, Santoro A, Savage G, Sawyer L, Scanlon T, Schaile D, Schamberger RD, Scheglov Y, Schellman H, Schieferdecker P, Schmitt C, Schwanenberger C, Schwartzman A, Schwienhorst R, Sekaric J, Sengupta S, Severini H, Shabalina E, Shamim M, Shary V, Shchukin AA, Shivpuri RK, Shpakov D, Siccardi V, Sidwell RA, Simak V, Sirotenko V, Skubic P, Slattery P, Smith RP, Snow GR, Snow J, Snyder S, Söldner-Rembold S, Song X, Sonnenschein L, Sopczak A, Sosebee M, Soustruznik K, Souza M, Spurlock B, Stark J, Steele J, Stolin V, Stone A, Stoyanova DA, Strandberg J, Strandberg S, Strang MA, Strauss M, Ströhmer R, Strom D, Strovink M, Stutte L, Sumowidagdo S, Svoisky P, Sznajder A, Talby M, Tamburello P, Taylor W, Telford P, Temple J, Tiller B, Titov M, Tokmenin VV, Tomoto M, Toole T, Torchiani I, Trefzger T, Trincaz-Duvoid S, Tsybychev D, Tuchming B, Tully C, Tuts PM, Unalan R, Uvarov L, Uvarov S, Uzunyan S, Vachon B, van den Berg PJ, van Eijk B, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vartapetian A, Vasilyev IA, Vaupel M, Verdier P, Vertogradov LS, Verzocchi M, Villeneuve-Seguier F, Vint P, Vlimant JR, Von Toerne E, Voutilainen M, Vreeswijk M, Wahl HD, Wang L, Wang MHLS, Warchol J, Watts G, Wayne M, Weber G, Weber M, Weerts H, Wermes N, Wetstein M, White A, Wicke D, Wilson GW, Wimpenny SJ, Wobisch M, Womersley J, Wood DR, Wyatt TR, Xie Y, Yacoob S, Yamada R, Yan M, Yasuda T, Yatsunenko YA, Yip K, Yoo HD, Youn SW, Yu C, Yu J, Yurkewicz A, Zatserklyaniy A, Zeitnitz C, Zhang D, Zhao T, Zhou B, Zhu J, Zielinski M, Zieminska D, Zieminski A, Zutshi V, Zverev EG. Measurement of the charge asymmetry in semileptonic Bs0 decays. PHYSICAL REVIEW LETTERS 2007; 98:151801. [PMID: 17501335 DOI: 10.1103/physrevlett.98.151801] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/08/2007] [Indexed: 05/15/2023]
Abstract
We have performed the first direct measurement of the time-integrated flavor untagged charge asymmetry in semileptonic Bs0 decays ASLs,unt by comparing the decay rate of Bs0-->micro+Ds-nuX, where Ds- -->phipi- and phi-->K+K-, with the charge-conjugate Bs0 decay rate. This sample was selected from 1.3 fb-1 of data collected by the D0 experiment in run II of the Fermilab Tevatron collider. We obtain ASLs,unt=[1.23+/-0.97(stat)+/-0.17(syst)]x10(-2). Assuming that Deltam(s)/Gamma(s)>>1, this result can be translated into a measurement of the CP-violating phase in Bs0 mixing: DeltaGamma(s)/Deltam(s)tanphi(s)=[2.45+/-1.93(stat)+/-0.35(syst)]x10(-2).
Collapse
|
522
|
Abazov VM, Abbott B, Abolins M, Acharya BS, Adams M, Adams T, Aguilo E, Ahn SH, Ahsan M, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Anastasoaie M, Ancu LS, Andeen T, Anderson S, Andrieu B, Anzelc MS, Arnoud Y, Arov M, Askew A, Asman B, Assis Jesus ACS, Atramentov O, Autermann C, Avila C, Ay C, Badaud F, Baden A, Bagby L, Baldin B, Bandurin DV, Banerjee P, Banerjee S, Barberis E, Barfuss AF, Bargassa P, Baringer P, Barnes C, Barreto J, Bartlett JF, Bassler U, Bauer D, Beale S, Bean A, Begalli M, Begel M, Belanger-Champagne C, Bellantoni L, Bellavance A, Benitez JA, Beri SB, Bernardi G, Bernhard R, Berntzon L, Bertram I, Besançon M, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Binder M, Biscarat C, Blackler I, Blazey G, Blekman F, Blessing S, Bloch D, Bloom K, Boehnlein A, Boline D, Bolton TA, Borissov G, Bos K, Bose T, Brandt A, Brock R, Brooijmans G, Bross A, Brown D, Buchanan NJ, Buchholz D, Buehler M, Buescher V, Burdin S, Burke S, Burnett TH, Busato E, Buszello CP, Butler JM, Calfayan P, Calvet S, Cammin J, Caron S, Carvalho W, Casey BCK, Cason NM, Castilla-Valdez H, Chakrabarti S, Chakraborty D, Chan K, Chan KM, Chandra A, Charles F, Cheu E, Chevallier F, Cho DK, Choi S, Choudhary B, Christofek L, Christoudias T, Claes D, Clément B, Clément C, Coadou Y, Cooke M, Cooper WE, Corcoran M, Couderc F, Cousinou MC, Cox B, Crépé-Renaudin S, Cutts D, Cwiok M, da Motta H, Das A, Davies B, Davies G, De K, de Jong P, de Jong SJ, De La Cruz-Burelo E, De Oliveira Martins C, Degenhardt JD, Déliot F, Demarteau M, Demina R, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Doidge M, Dominguez A, Dong H, Dudko LV, Duflot L, Dugad SR, Duggan D, Duperrin A, Dyer J, Dyshkant A, Eads M, Edmunds D, Ellison J, Elvira VD, Enari Y, Eno S, Ermolov P, Evans H, Evdokimov A, Evdokimov VN, Ferapontov AV, Ferbel T, Fiedler F, Filthaut F, Fisher W, Fisk HE, Ford M, Fortner M, Fox H, Fu S, Fuess S, Gadfort T, Galea CF, Gallas E, Galyaev E, Garcia C, Garcia-Bellido A, Gavrilov V, Gay P, Geist W, Gelé D, Gerber CE, Gershtein Y, Gillberg D, Ginther G, Gollub N, Gómez B, Goussiou A, Grannis PD, Greenlee H, Greenwood ZD, Gregores EM, Grenier G, Gris P, Grivaz JF, Grohsjean A, Grünendahl S, Grünewald MW, Guo F, Guo J, Gutierrez G, Gutierrez P, Haas A, Hadley NJ, Haefner P, Hagopian S, Haley J, Hall I, Hall RE, Han L, Hanagaki K, Hansson P, Harder K, Harel A, Harrington R, Hauptman JM, Hauser R, Hays J, Hebbeker T, Hedin D, Hegeman JG, Heinmiller JM, Heinson AP, Heintz U, Hensel C, Herner K, Hesketh G, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Hoeth H, Hohlfeld M, Hong SJ, Hooper R, Houben P, Hu Y, Hubacek Z, Hynek V, Iashvili I, Illingworth R, Ito AS, Jabeen S, Jaffré M, Jain S, Jakobs K, Jarvis C, Jenkins A, Jesik R, Johns K, Johnson C, Johnson M, Jonckheere A, Jonsson P, Juste A, Käfer D, Kahn S, Kajfasz E, Kalinin AM, Kalk JM, Kalk JR, Kappler S, Karmanov D, Kasper J, Kasper P, Katsanos I, Kau D, Kaur R, Kehoe R, Kermiche S, Khalatyan N, Khanov A, Kharchilava A, Kharzheev YM, Khatidze D, Kim H, Kim TJ, Kirby MH, Klima B, Kohli JM, Konrath JP, Kopal M, Korablev VM, Kotcher J, Kothari B, Koubarovsky A, Kozelov AV, Krop D, Kryemadhi A, Kuhl T, Kumar A, Kunori S, Kupco A, Kurca T, Kvita J, Lam D, Lammers S, Landsberg G, Lazoflores J, Lebrun P, Lee WM, Leflat A, Lehner F, Lesne V, Leveque J, Lewis P, Li J, Li L, Li QZ, Lietti SM, Lima JGR, Lincoln D, Linnemann J, Lipaev VV, Lipton R, Liu Z, Lobo L, Lobodenko A, Lokajicek M, Lounis A, Love P, Lubatti HJ, Lynker M, Lyon AL, Maciel AKA, Madaras RJ, Mättig P, Magass C, Magerkurth A, Makovec N, Mal PK, Malbouisson HB, Malik S, Malyshev VL, Mao HS, Maravin Y, Martin B, McCarthy R, Melnitchouk A, Mendes A, Mendoza L, Mercadante PG, Merkin M, Merritt KW, Meyer A, Meyer J, Michaut M, Miettinen H, Millet T, Mitrevski J, Molina J, Mommsen RK, Mondal NK, Monk J, Moore RW, Moulik T, Muanza GS, Mulders M, Mulhearn M, Mundal O, Mundim L, Nagy E, Naimuddin M, Narain M, Naumann NA, Neal HA, Negret JP, Neustroev P, Nilsen H, Noeding C, Nomerotski A, Novaes SF, Nunnemann T, O'Dell V, O'Neil DC, Obrant G, Ochando C, Oguri V, Oliveira N, Onoprienko D, Oshima N, Osta J, Otec R, Otero y Garzón GJ, Owen M, Padley P, Pangilinan M, Parashar N, Park SJ, Park SK, Parsons J, Partridge R, Parua N, Patwa A, Pawloski G, Perea PM, Peters K, Peters Y, Pétroff P, Petteni M, Piegaia R, Piper J, Pleier MA, Podesta-Lerma PLM, Podstavkov VM, Pogorelov Y, Pol ME, Pompos A, Pope BG, Popov AV, Potter C, Prado da Silva WL, Prosper HB, Protopopescu S, Qian J, Quadt A, Quinn B, Rangel MS, Rani KJ, Ranjan K, Ratoff PN, Renkel P, Reucroft S, Rijssenbeek M, Ripp-Baudot I, Rizatdinova F, Robinson S, Rodrigues RF, Royon C, Rubinov P, Ruchti R, Sajot G, Sánchez-Hernández A, Sanders MP, Santoro A, Savage G, Sawyer L, Scanlon T, Schaile D, Schamberger RD, Scheglov Y, Schellman H, Schieferdecker P, Schmitt C, Schwanenberger C, Schwartzman A, Schwienhorst R, Sekaric J, Sengupta S, Severini H, Shabalina E, Shamim M, Shary V, Shchukin AA, Shivpuri RK, Shpakov D, Siccardi V, Sidwell RA, Simak V, Sirotenko V, Skubic P, Slattery P, Smirnov D, Smith RP, Snow GR, Snow J, Snyder S, Söldner-Rembold S, Sonnenschein L, Sopczak A, Sosebee M, Soustruznik K, Souza M, Spurlock B, Stark J, Steele J, Stolin V, Stone A, Stoyanova DA, Strandberg J, Strandberg S, Strang MA, Strauss M, Ströhmer R, Strom D, Strovink M, Stutte L, Sumowidagdo S, Svoisky P, Sznajder A, Talby M, Tamburello P, Taylor W, Telford P, Temple J, Tiller B, Tissandier F, Titov M, Tokmenin VV, Tomoto M, Toole T, Torchiani I, Trefzger T, Trincaz-Duvoid S, Tsybychev D, Tuchming B, Tully C, Tuts PM, Unalan R, Uvarov L, Uvarov S, Uzunyan S, Vachon B, van den Berg PJ, van Eijk B, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vartapetian A, Vasilyev IA, Vaupel M, Verdier P, Vertogradov LS, Verzocchi M, Villeneuve-Seguier F, Vint P, Vlimant JR, Von Toerne E, Voutilainen M, Vreeswijk M, Wahl HD, Wang L, Wang MHLS, Warchol J, Watts G, Wayne M, Weber G, Weber M, Weerts H, Wenger A, Wermes N, Wetstein M, White A, Wicke D, Wilson GW, Wimpenny SJ, Wobisch M, Wood DR, Wyatt TR, Xie Y, Yacoob S, Yamada R, Yan M, Yasuda T, Yatsunenko YA, Yip K, Yoo HD, Youn SW, Yu C, Yu J, Yurkewicz A, Zatserklyaniy A, Zeitnitz C, Zhang D, Zhao T, Zhou B, Zhu J, Zielinski M, Zieminska D, Zieminski A, Zutshi V, Zverev EG. Lifetime difference and CP-violating phase in the Bs0 system. PHYSICAL REVIEW LETTERS 2007; 98:121801. [PMID: 17501111 DOI: 10.1103/physrevlett.98.121801] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/10/2007] [Indexed: 05/15/2023]
Abstract
From an analysis of the decay Bs0-->J/psi phi, we obtain the width difference between the light and heavy mass eigenstates DeltaGamma identical with (GammaL-GammaH)=0.17+/-0.09(stat)+/-0.02(syst) ps-1 and the CP-violating phase phis=-0.79+/-0.56(stat)(-0.01)(+0.14)(syst). Under the hypothesis of no CP violation (phis identical with 0), we obtain 1/Gamma=tau(Bs0)=1.52+/-0.08(stat)(-0.03)(+0.01)(syst) ps and DeltaGamma=0.12(-0.10)(+0.08)(stat)+/-0.02(syst) ps-1. The data sample corresponds to an integrated luminosity of about 1.1 fb-1 accumulated with the D0 detector at the Fermilab Tevatron collider. This is the first direct measurement of the CP-violating mixing phase in the Bs0 system.
Collapse
|
523
|
Abstract
The dental pulp is a unique tissue and its importance in the long-term prognosis of the tooth is often ignored by clinicians. It is unique in that it resides in a rigid chamber which provides strong mechanical support and protection from the microbial rich oral environment. If this rigid shell loses its structural integrity, the pulp is under the threat of the adverse stimuli from the mouth, such as caries, cracks, fractures and open restoration margins, all of which provide pathways for micro-organisms and their toxins to enter the pulp. The pulp initially responds to irritation by becoming inflamed and, if left untreated, this will progress to pulp necrosis and infection. The inflammation will also spread to the surrounding alveolar bone and cause periapical pathosis. The magnitude of pulp-related problems should not be underestimated since their most serious consequence is oral sepsis, which can be life threatening, and hence correct diagnosis and management are essential. Clinicians must have a thorough understanding of the physiological and pathological features of the dental pulp as well as the biological consequences of treatment interventions.
Collapse
|
524
|
Abstract
Many different classification systems have been advocated for pulp diseases. However, most of them are based on histopathological findings rather than clinical findings which leads to confusion since there is little correlation between them. Most classifications mix clinical and histological terms resulting in misleading terminology and diagnoses. This in turn leads to further confusion and uncertainty in clinical practice when a rational treatment plan needs to be established in order to manage a specific pathological entity. A simple, yet practical classification of pulp diseases which uses terminology related to clinical findings is proposed. This classification will help clinicians understand the progressive nature of the pulp disease processes and direct them to the most appropriate and conservative treatment strategy for each condition. With a comprehensive knowledge of the pathophysiology of pain and inflammation in the pulp tissues, clinicians may accomplish this task with confidence.
Collapse
|
525
|
Lin F, Yu C, Jiang T, Li K, Chan P. Diffusion tensor tractography-based group mapping of the pyramidal tract in relapsing-remitting multiple sclerosis patients. AJNR Am J Neuroradiol 2007; 28:278-82. [PMID: 17296994 PMCID: PMC7977424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
BACKGROUND AND PURPOSE Many studies have reported abnormal changes in relapsing-remitting multiple sclerosis (RRMS) by histogram and region-of-interest-based methods by using diffusion tenor imaging. However, there are few studies on specific white matter fiber tracts of RRMS. Our study sought to use diffusion tensor tractography-based group mapping to investigate the presence of abnormal diffusion in the normal-appearing pyramidal tract (PYT) of RRMS and its possible mechanism. METHODS A PYT probability map was first constructed from data on 20 healthy patients based on the deterministic-based tractography method. The PYT probability map was then applied to 29 RRMS patients to calculate diffusion indices of the PYT. In this study, 4 quantitative indices-fractional anisotropy (FA), directionally averaged diffusion coefficient (D(av)), axial diffusion coefficient (lambda(1)), and radial diffusion coefficient (lambda(23))-were used to characterize the abnormal diffusion. RESULTS Compared with healthy controls, RRMS patients had a significantly higher D(av) and lambda(23) but a lower FA and a trend toward a lower lambda(1) in the normal-appearing PYT. In RRMS patients, PYT lesions had a significantly higher lambda(23) and a lower FA, but there were no differences for D(av) and lambda(1) when compared with the normal-appearing PYT. Moreover, the diffusion indices derived from the normal-appearing PYT were significantly correlated with PYT lesion volumes by using the Spearman correlation analysis. CONCLUSION Our findings confirm the presence of abnormal diffusion in the normal-appearing PYT of RRMS patients and suggest that wallerian degeneration might be its mechanism.
Collapse
|